Literature DB >> 28165561

Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer.

D-Q Chen1, X-D Zheng, Y Cao, X-D He, W-Q Nian, X-H Zeng, X-Y Liu.   

Abstract

OBJECTIVE: Breast cancer is the most common malignant tumor in women. However, the detailed mechanisms of its tumorigenesis remain largely unknown. Evidence and data have shown that abnormality in expression of Long non-coding RNA (LncRNA) is closely related to tumorigenesis. The aim of this study is to identify the detailed mechanisms of LncRNA LINC00628 in breast cancer. PATIENTS AND METHODS: The expression of LINC00628 in breast cancer tissues, adjacent non-cancerous tissues and cell lines were detected by qRT-PCR. Kaplan-Meier method and log-rank test were applied to analyze the overall survival of patients with low and high expression level of LINC00628 respectively. The LCC2 and MCF-7 cells were transfected with LINC00628 and the proliferation, invasion and migration were examined. The cell cycle distribution and cell apoptosis rate in LCC2 and MCF-7 cells after transfection with LINC00628 were explored by flow cytometry. The relative expression level of Bcl-2, Bax and Caspase-3 protein in LCC2 and MCF-7 cells after transfection with LINC00628 was detected by Western blotting.
RESULTS: The relative expression level of LINC00628 in breast cancer tissues and cell lines were significantly decreased and the low expression level of LINC00628 has a poorer prognosis and lower overall survival rate. The overexpression of LINC00628 suppressed breast cancer cells proliferation, invasion and migration. Further, with the overexpression of LINC00628, cell cycle was arrested in G0/G1 phase in breast cancer cells and cell apoptosis was promoted. The relative expression of Caspase-3 and Bax protein were significantly increased and the relative expression of Bcl-2 protein was significantly decreased after transfection with LINC00628.
CONCLUSIONS: The expression of LINC00628 was decreased in breast cancer. The overexpression of LINC00628 suppressed the proliferation, invasion and migration of breast cancer cells and promoted cell apoptosis associated with the regulation of Bcl-2/Bax/Caspase-3 signal pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28165561

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer.

Authors:  R-K Li; J- Gao; L-H Guo; G-Q Huang; W-H Luo
Journal:  Cancer Gene Ther       Date:  2017-07-21       Impact factor: 5.987

2.  LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.

Authors:  You-Quan Wang; Guo Huang; Juan Chen; Hong Cao; Wen-Ting Xu
Journal:  Breast Cancer Res Treat       Date:  2021-03-29       Impact factor: 4.872

3.  A long non-coding RNA LINC00461-dependent mechanism underlying breast cancer invasion and migration via the miR-144-3p/KPNA2 axis.

Authors:  Qiang Zhang; Xiaoyan Jin; Wenbiao Shi; Xin Chen; Wenyang Pang; Xiaodong Yu; Linjun Yang
Journal:  Cancer Cell Int       Date:  2020-04-26       Impact factor: 5.722

4.  Downregulation of LINC02615 Is Correlated with The Breast Cancer Progress: A Novel Biomarker for Differential Identification of Breast Cancer Tissues.

Authors:  Sayed Rasoul Zaker; Kamran Ghaedi
Journal:  Cell J       Date:  2021-08-29       Impact factor: 2.479

5.  LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.

Authors:  Tingting Liu; Shuangshuang Xu; Xiaoxin Liu
Journal:  Oncol Lett       Date:  2021-12-21       Impact factor: 2.967

6.  Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma.

Authors:  Lu Lu; Le-Ping Liu; Qiang-Qiang Zhao; Rong Gui; Qin-Yu Zhao
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 7.  EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Authors:  Ke-Sin Yan; Chia-Yuan Lin; Tan-Wei Liao; Cheng-Ming Peng; Shou-Chun Lee; Yi-Jui Liu; Wing P Chan; Ruey-Hwang Chou
Journal:  Int J Mol Sci       Date:  2017-05-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.